EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 Listed Suppliers, $ API Reference Price

2 API Suppliers
2 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 4,450

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

8DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Mb-07811, 852948-13-1, Mb07811, Vk-2809, Vk2809, Unii-3z11398fnq

Molecular Formula

C₂₈H₃₂ClO₅P

Molecular Weight

515.0 g/mol

InChI Key

LGGPZDRLTDGYSQ-JADSYQMUSA-N

FDA UNII

3Z11398FNQ

VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).

1 2D Structure

VK2809

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,25-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol

2.1.2 InChI

InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1

2.1.3 InChI Key

LGGPZDRLTDGYSQ-JADSYQMUSA-N

2.1.4 Canonical SMILES

CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCP3(=O)OCCC(O3)C4=CC(=CC=C4)Cl

2.1.5 Isomeric SMILES

CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl

2.2 Other Identifiers

2.2.1 UNII

3Z11398FNQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

2. Mb 07811

3. Mb-07811

4. Mb07811

5. Vk2809

2.3.2 Depositor-Supplied Synonyms

1. Mb-07811

2. 852948-13-1

3. Mb07811

4. Vk-2809

5. Vk2809

6. Unii-3z11398fnq

7. Chembl457748

8. 3z11398fnq

9. Mb-07811 (vk-2809)

10. 4-[[4-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol

11. (2r,4s)-4-(3-chlorophenyl)-2-((4-(4-hydroxy-3-isopropylbenzyl)-3,5-dimethylphenoxy)methyl)-1,3,2-dioxaphosphinane 2-oxide

12. Mb 07811

13. Schembl282796

14. Gtpl12768

15. Dtxsid501005783

16. Ex-a3394

17. Bdbm50401076

18. Akos040742104

19. Db15137

20. Compound 22c [pmid: 18975928]

21. Trans-(s)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxo-(1,3,2)dioxaphosphorinane

22. Hy-111288

23. Cs-0034844

24. Q27258223

25. (2r,4s)-4-(3-chlorophenyl)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-2-oxido-(1,3,2)-dioxaphosphonane

26. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

27. 4-(3-chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2lambda~5~-dioxaphosphinan-2-one

2.4 Create Date

2007-02-21

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₃₂ClO₅P
Molecular Weight	515.0 g/mol
XLogP3	6.9
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	65
Heavy Atom Count	35
Formal Charge	0
Complexity	708
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in hyperlipidemia.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

Studies indicate that targeting TR agonists to the liver has the potential to lower both LDL-cholesterol (the "bad" cholesterol) and both hepatic and plasma triglyceride levels.

API SUPPLIERS